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In patients without a history of diabetes mellitus, increased levels of glycated hemoglobin
(HbA1c) are associated with higher cardiovascular risk. The relation between undetected
diabetes and clinical outcome after percutaneous coronary intervention is unknown. To inves-
tigate whether these patients may have an increased risk of periprocedural myocardial infarc-
tion (PMI), the most frequent adverse event after percutaneous coronary intervention, we
assessed patients of the TWENTE trial (a randomized, controlled, second-generation drug-
eluting stent trial) in whom HbA1c data were available. Patients were classified as known
diabetics or patients without a history of diabetes who were subdivided into undetected
diabetics (HbA1c >6.5%) and nondiabetics (HbA1c <6.5%). Systematic measurement of
cardiac biomarkers and electrocardiographic assessment were performed. One-year clinical
outcome was also compared. Of 626 patients, 44 (7%) were undetected diabetics, 181 (29%)
were known diabetics, and 401 (64%) were nondiabetics. In undetected diabetics the PMI rate
was higher than in nondiabetics (13.6% vs 3.7%, p 0.01) and known diabetics (13.6% vs 6.1%,
p  0.11). Multivariate analysis adjusting for covariates confirmed a significantly higher PMI
risk in undetected diabetics compared to nondiabetics (odds ratio 6.13, 95% confidence interval
2.07 to 18.13, p 0.001) and known diabetics (odds ratio 3.73, 95% confidence interval 1.17 to
11.89, p  0.03). After 1 year, target vessel MI rate was significantly higher in undetected
diabetics (p  0.02) than in nondiabetics, which was related mainly to differences in PMI.
Target vessel failure was numerically larger in unknown diabetics than in nondiabetics, but this
difference did not reach statistical significance (13.6% vs 8.0%, p  0.25). In conclusion,
undetected diabetics were shown to have an increased risk of PMI. © 2012 Elsevier Inc. All
rights reserved. (Am J Cardiol 2012;110:1561–1567)aDepartment of Cardiology, Thoraxcentrum, Twente, and Medisch
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http://dx.doi.org/10.1016/j.amjcard.2012.07.019Periprocedural myocardial infarction (PMI) is the most
frequent adverse event after percutaneous coronary inter-
ventions (PCI) outside the setting of ST-segment elevation
MI. It has previously been shown that PMI is not necessarily
a benign event and that patients with PMI may have a worse
prognosis.1,2 Diabetic patients may be particularly prone to
PMI because this disease is associated with dyslipidemia,
hypercoagulability, increased atheroma burden, vessel wall
inflammation, and development of vulnerable plaques.3–5 In
patients with undetected diabetes, metabolic dysregulation
and a long-term hyperglycemic state may result in a similar,
perhaps even higher, PMI risk. The relation between in-
creased glycated hemoglobin (HbA1c) and the occurrence
of PMI has not yet been examined. We hypothesized that
undetected diabetes and diabetes mellitus may be related to
PMI. In the present study, we therefore assessed this hy-
pothesis in patients of the The Real-World Endeavor Res-
olute Versus XIENCE V Drug-Eluting Stent Study
(TWENTE)—a randomized controlled trial that compared 2
second-generation drug-eluting stents (DESs) in patients
www.ajconline.org
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1562 The American Journal of Cardiology (www.ajconline.org)with various clinical presentations with the exception of
ST-segment elevation MI.6
Methods
The present study was performed in a subpopulation of
patients enrolled in the TWENTE trial (http://www.
ClinicalTrials.gov, NCT01066650) in whom HbA1c lev-
els were measured at the time of the index PCI procedure
(1 month). Details of the TWENTE study have previ-
ously been described.6 In brief, TWENTE is an investi-
ator-initiated, patient-blinded, randomized noninferior-
ty study with limited exclusion criteria in a “real-world”
atient population treated at the Thoraxcentrum Twente
n Enschede, the Netherlands. From June 2008 through
ugust 2010, 1,391 patients with an indication for PCI
ith DES implantation were randomized for treatment
ith the second-generation Resolute stent (Medtronic,
nc., Santa Rosa, California) or Xience V stent (Abbott
ascular, Santa Clara, California). There were no angio-
raphic exclusion criteria. The most important exclusion
riterion was recent ST-segment elevation MI.6 The
TWENTE trial was approved by the institutional ethics
committee, complied with the Declaration of Helsinki,
and all patients provided a written informed consent.
All patients were pretreated with acetylsalicylic acid and
clopidogrel. At discharge we prescribed the combination of
Table 1
Baseline characteristics of patients
Study Population
(n  626)
Undet
(n
Age (years) 64.7  9.9 66.8
Glycated hemoglobin (%) 6.25  0.94 6.95
Men 450 (72%) 3
Body mass index (kg/m2) 28.0  4.1 27.7
Insulin treatment 67 (11%)
Insulin treatment and oral glucose-lowering
medication
43 (7%)
Chronic renal failure* 24 (4%)
Arterial hypertension 382 (61%) 3
Hypercholesterolemia 402/610 (66%) 24/3
Current smoker 135 (22%) 1
Family history of coronary artery disease 358 (57%) 1
Myocardial infarction (any) 186 (30%) 1
Previous percutaneous coronary intervention 139 (22%)
Previous coronary artery bypass grafting 70 (11%)
Clinical indication
Stable angina pectoris 426 (68%) 3
Unstable angina 120 (19%) 1
Non–ST-segment elevation myocardial
infarction
80 (13%)
Clinical indication: acute coronary
syndrome
200 (32%) 1
Left ventricular ejection fraction 30%† 15/473 (3%) 1/3
Data are presented as number (percentage) or mean  SD.
* Chronic renal failure defined by serum creatinine level 130 mol/L
† Left ventricular ejection fraction assessed with ultrasound, magnetic r
DM  diabetes mellitus.acetylsalicylic acid 100 mg 1 time/day indefinitely and clopi- Mdogrel 75 mg 1 time/day for 1 year. Predilation, direct stenting,
stent postdilatation, and/or use of glycoprotein IIb/IIIa antag-
onists were permitted at the operators’ discretion.
The study population was grouped into patients with a
known history of diabetes mellitus versus patients without a
history of diabetes. Patients without a history of diabetes
were then subdivided based on a cut-off HbA1c value of
6.5%; patients with an HbA1c level 6.5% were classified
as undetected diabetics and patients with an HbA1c level
6.5% as nondiabetics.7 Assessment of HbA1c was per-
formed with a COBAS Integra 800 analysis system (Roche
Diagnostics, Basel, Switzerland) at the department of clin-
ical chemistry of our center.
In all patients cardiac biomarkers and electrocardio-
grams were systematically assessed and analyzed before
and after PCI to identify PMI.8 Cardiac biomarker mea-
urements were scheduled before PCI and 6 to 18 hours
fter PCI, with subsequent serial measurements for rele-
ant biomarker increases or complaints until peak in-
rease was established. We used the PMI definition of the
cademic Research Consortium: creatine kinase (CK)
2 times upper limit of normal with increase of CK-MB
nd/or troponin. If baseline cardiac biomarkers were
bove the upper limit of normal or MI was in progress,
MI was established when (1) there was recurrent chest
ain or new electrocardiographic changes consistent with
M No DM
(n  401)
Known DM
(n  181)
p Value
Undetected vs
No DM
Undetected vs
Known DM
64.1  9.8 65.5  0.3 0.09 0.46
5.77  0.31 7.13  1.15 0.001 0.32
) 295 (74%) 123 (68%) 0.91 0.54
27.5  3.8 29.2  4.6 0.75 0.10
— 67 (37%)
— 43 (24%)
11 (3%) 11 (6%) 0.50 0.70
) 227 (57%) 125 (69%) 0.28 0.91
) 246/392 (63%) 132/179 (74%) 0.88 0.25
) 90 (22%) 34 (19%) 0.70 0.36
) 235 (59%) 107 (59%) 0.02 0.02
) 118 (29%) 53 (29%) 0.52 0.53
) 84 (21%) 49 (27%) 0.25 0.06
43 (11%) 23 (13%) 0.74 0.51
0.69 0.51
) 282 (70%) 114 (63%)
) 72 (18%) 38 (21%)
47 (12%) 29 (16%)
) 119 (30%) 67 (37%) 0.77 0.52
6/294 (2%) 8/144 (6%) 0.75 0.51
e imaging, or left ventricular angiography.ected D
 44)
 9.7
 0.74
2 (73%
 2.8
—
—
2 (5%)
0 (68%
9 (62%
1 (25%
6 (36%
5 (34%
6 (14%
4 (9%)
0 (68%
0 (23%
4 (9%)
4 (32%
5 (3%)
.
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1563Coronary Artery Disease/Periprocedural MI in Undetected Diabeticsnormal or (2) if increased CK after the index MI peaked
and the CK level returned below the upper limit of
normal when there was an increase of CK 2 times upper
imit of normal or (3) if increased CK after the index MI
eaked and the CK level did not return below the upper
imit of normal, an increase in CK 50% above the
revious level, and 2 times upper limit of normal con-
rmed by an increase of CK-MB and/or troponin.8 Clin-
ical end points included target vessel failure within 1 year
(composite end point consisting of cardiac death, target-
vessel related MI [or not attributable to a nontarget ves-
sel], or clinically driven target vessel revascularization),
individual components of target vessel failure, stent
thrombosis and a patient-oriented composite end point
consisting of all-cause mortality, any MI, and any repeat
revascularization. All clinical end points including stent
thrombosis were defined according to the Academic Re-
search Consortium.8,9
Clinical follow-up data were obtained at visits at outpa-
tient clinics or, if not feasible, by telephone follow-up
and/or medical questionnaire. Follow-up data were avail-
able in all patients; 2 patients withdrew informed consent
before follow-up at 1 year and thus are not included in the
follow-up analysis. Processing of clinical data and adjudi-
cation of all adverse clinical events were performed by an
independent external contract research organization (Cardi-
Table 2
Angiographic and procedural characteristics
Study
Population
(n  626)
Target lesion coronary artery
Left anterior descending 316 (51%)
Left circumflex 216 (35%)
Right 222 (36%)
Left main 24 (96%)
Bypass graft 19 (3%)
Multivessel treatment 156 (25%)
Total lesions treated per patient
1 384 (61%)
2 172 (28%)
3 70 (11%)
Number of stents placed 2.08  1.29
American College of Cardiology/American Heart
Association class B2 or C lesion treated
361 (58%)
De novo coronary lesions only* 582 (93%)
1 chronic total occlusion 57 (9%)
1 bifurcation 152 (24%)
1 bifurcation with side branch treatment 96 (15%)
1 in-stent restenosis 28 (5%)
1 small vessel (reference vessel diameter 2.75 mm) 419 (67%)
1 lesion length 27 mm 141 (23%)
Preprocedural Thrombolysis In Myocardial Infarction
flow (grades 0–1)
43 (7%)
Aggressive stent postdilatation of 18 atm 476 (88%)
Side branch occlusion 16 (2.6%)
Distal embolization 3 (0.5%)
Data are presented as number (percentage) or mean  SD.
* Including chronic total occlusion but not grafts and in-stent restenosi
Abbreviation as in Table 1.alysis, Rotterdam, the Netherlands). sAll statistical analyses were performed with SPSS 15.0
(SPSS, Inc., Chicago, Illinois).
When comparing undetected diabetics to nondiabetics
and undetected diabetics to known diabetics, differences
in categorical variables were assessed with chi-square or
Fisher’s exact tests, as appropriate, whereas continuous
variables were assessed with the Wilcoxon rank-sum test
or Student’s t test, as appropriate. Unless otherwise spec-
fied, p values and confidence intervals (CIs) were
-sided and a p value 0.05 was considered statistically
ignificant. Univariate and multivariate logistic regres-
ion analyses were performed to evaluate diabetic status
s an independent predictor of PMI in the subpopulation
f undetected diabetics and nondiabetics and in the sub-
opulation of undetected diabetics and known diabetics.
ll variables were evaluated as possible predictors, and
nly those with significance at a p value 0.15 for PMI
ere considered candidate variables for multivariate lo-
istic regression analysis and were assessed for their
elation with diabetes. If this relation was also present
ith significance at a p value 0.15, they were included
n the model. To obtain a parsimonious model, we started
ith all candidate variables. Subsequently, we eliminated
he variables with the highest p value step by step until
he estimate for diabetes changed by 10% or only
tected
M
44)
No DM
(n  401)
Known DM
(n  181)
p Value
Undetected vs
No DM
Undetected vs
Known DM
6%) 213 (53%) 100 (55%) 0.04 0.16
9%) 140 (35%) 59 (33%) 0.62 0.45
4%) 137 (34%) 70 (39%) 0.99 0.57
%) 13 (3%) 9 (5%) 0.65 0.91
%) 12 (3%) 6 (3%) 0.79 0.72
4%) 106 (26%) 44 (24%) 0.06 0.13
0.13 0.21
6%) 241 (60%) 114 (63%)
2%) 110 (27%) 48 (27%)
%) 50 (13%) 19 (11%)
0.99 2.10  1.29 2.11  1.34 0.08 0.10
3%) 242 (60%) 100 (55%) 0.03 0.15
6%) 374 (93%) 166 (92%) 0.58 0.40
%) 41 (10%) 13 (7%) 0.47 0.93
4%) 92 (23%) 45 (25%) 0.10 0.21
1%) 59 (15%) 28 (16%) 0.32 0.42
%) 17 (4%) 10 (6%) 0.53 0.37
4%) 275 (69%) 116 (64%) 0.50 0.96
1%) 90 (22%) 46 (25%) 0.09 0.05
%) 29 (7%) 12 (7%) 0.51 0.61
1%) 300 (88%) 146 (90%) 0.28 0.12
.3%) 13 (3.2%) 2 (1.1%) 0.73 0.55
%) 1 (0.2%) 2 (1.1%) 0.74 0.48Unde
D
(n 
16 (3
17 (3
15 (3
2 (5
1 (2
6 (1
29 (6
14 (3
1 (2
1.75 
19 (4
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3 (7
15 (3
9 (2
1 (2
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Of all patients enrolled in the TWENTE trial, 626 had
HbA1c measurements within the predefined time frame and
formed the study population of the present analysis. Patients
in the study population had more diabetes mellitus (29% vs
16%, p 0.001), chronic renal failure (3.8% vs 1.8%, p 
0.02), hypertension (61% vs 51%, p 0.001), hypercholes-
erolemia (66% vs 54%, p 0.001), and family history of
oronary artery disease (57% vs 50%, p  0.01) than
WENTE trial patients without HbA1c measurements.
Of the study population 181 (29%) had a history of
iabetes mellitus. In addition, 445 patients of the study
opulation (71%) had no history of diabetes mellitus; ac-
ording to HbA1c levels, 44 patients of the study population
ere classified as undetected diabetics (7.0%) and 401 as
ondiabetic patients (64%).
Baseline characteristics of the study population and sub-
roups are presented in Table 1. Compared to known dia-
etic patients and nondiabetic patients, undetected diabetics
howed many similarities in baseline characteristics but less
ften tended to have a family history of coronary artery
isease (p  0.02 for the 2 groups). As may be expected,
Figure 1. Incidence of periprocedural myocardial infarction (PMI) stratified
by diabetic state in patients without a history of diabetes mellitus (DM) and
glycated hemoglobin 6.5% (No DM), patients with a history of diabetes
mellitus (Known DM), and patients without a history of diabetes mellitus
and glycated hemoglobin 6.5% (Undetected DM). The p values were
alculated with multivariate logistic regression analysis.
Table 3
Medication at discharge
Study Population
(n  626)
Unde
(n
Antiplatelet therapy
Acetylsalicylic acid 619 (99%) 44
Clopidogrel 625 (100%) 44
Other medication
Statin 536 (86%) 35
 Blocker 518 (83%) 34
Angiotensin-converting enzyme inhibitor/
angiotensin receptor blocker
321 (51%) 27
Data are presented as number (percentage).
Abbreviation as in Table 1.ean HbA1c levels differed across groups and undetected niabetics had higher HbA1c levels compared to nondiabetic
atients (6.95 vs 5.77, p 0.001).
Angiographic and procedural characteristics are pre-
ented in Table 2. Undetected diabetics were less frequently
reated for left anterior descending coronary artery lesions
36% vs 53%, p  0.04) and type B2/C lesions (43.2% vs
0.3%, p  0.03) compared to nondiabetic patients. Dia-
etic patients were treated more frequently for long lesions
27 mm) than nondiabetic patients (25% vs 22%, p 
.05). Side branch occlusion was observed in 2.6% of pa-
ients and distal embolization in 0.5%, with no significant
ifference between groups. Medication at discharge did not
iffer between groups except for higher rates of angioten-
in-converting enzyme inhibitor and/or angiotensin receptor
locker prescription in undetected diabetics compared to
Figure 2. Multivariate adjusted odds ratios for independent predictors of
periprocedural myocardial infarction in undetected diabetics and nondia-
betics (A) and in undetected diabetics and known diabetics (B). Abbrevi-
ations as in Figure 1.
DM No DM
(n  401)
Known DM
(n  181)
p Value
Undetected vs
No DM
Undetected vs
Known DM
) 397 (99%) 178 (98%) 0.51 0.39
) 400 (100%) 181 (100%) 1.00 1.00
345 (86%) 156 (86%) 0.25 0.27
331 (83%) 153 (85%) 0.39 0.25
180 (45%) 114 (63%) 0.04 0.84tected
 44)
(100%
(100%
(80%)
(77%)
(61%)ondiabetics (p  0.04; Table 3).
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1565Coronary Artery Disease/Periprocedural MI in Undetected DiabeticsPMI occurred in 32 patients (5.1%) of the study popu-
lation. In undetected diabetics, PMI occurred more fre-
quently than in nondiabetic patients (13.6% [6 of 44] vs
3.7% [15 of 401], p  0.01) and known diabetics (13.6% [6
f 44] vs 6.1% [11 of 181], p  0.11; Figure 1).
In a model with only nondiabetic patients and undetected
iabetics, variables with a univariate association (p 0.15)
or PMI and diabetic state were multivessel treatment, num-
er of lesions treated, bifurcations, and number of stents
laced. Diabetic state and number of stents placed turned
ut to be independent predictors of PMI in a multivariate
odel. Using nondiabetic patients as the reference group,
he adjusted odds ratio (OR) of PMI was 6.13 in undetected
iabetic patients (95% CI 2.07 to 18.13, p  0.001). In
ddition, number of stents placed was independently asso-
iated with a significantly higher rate of PMI, with an OR of
.80 (95% CI 1.36 to 2.38, p 0.001) per additional stent
laced (Figure 2).
In a separate model with only known diabetics and un-
etected diabetics, variables with a univariate association
p 0.15) for PMI and diabetic state were treatment of 1
ong lesion (27 mm) and number of stents placed. Dia-
etic state and treatment of 1 long lesion (27 mm) were
ignificant independent predictors of PMI. Using known
iabetic patients as the reference group, the adjusted OR of
MI was 3.73 in undetected diabetic patients (95% CI 1.17
o 11.89, p 0.03). In addition, treatment of1 long lesion
27 mm) was independently associated with a signifi-
antly higher rate of PMI (OR 5.87, 95% CI 1.98 to 17.41,
 0.001; Figure 2).
Clinical follow-up at 1 year is presented in Table 4. Rate
f target vessel MI was significantly higher in undetected
iabetics (p  0.02) than in nondiabetic patients caused by
ncreased PMI rates in that group (p  0.01). In addition,
ates of target vessel failure and patient composite end point
ended to be lower in nondiabetics compared to undetected
iabetics, but this was statistically not significant. When
Table 4
Clinical outcome at one year
Undetected DM
(n  44)
All-cause death 0 (0%)
Cardiac death 0 (0%)
Target vessel revascularization 1 (2.3%)
Target vessel myocardial infarction 6 (13.6%)
Periprocedural myocardial infarction 6 (13.6%)
Spontaneous myocardial infarction 0 (0%)
Target vessel failure 6 (13.6%)
Patient-oriented composite end point 6 (13.6%)
Target vessel failure without periprocedural
myocardial infarction
1 (2.3%)
Patient-oriented composite end point without
periprocedural myocardial infarction
1 (2.3%)
Definite or probable stent thrombosis 0 (0%)
Data are presented as number of patients (percentage). Patient-oriented
infarction, or any revascularization.
Abbreviation as in Table 1.nalyzing event rates after discharge from the hospital (thusot including PMI), occurrence of target vessel failure and
he patient-oriented composite end point did not differ be-
ween groups. Definite or probable stent thrombosis rates
ere relatively low and similar between groups.
iscussion
The main finding of the present study is that undetected
iabetics (i.e., patients without a history of diabetes mellitus
ut with HbA1c levels 6.5%) had a significantly higher
isk of PMI compared to nondiabetic patients. Undetected
iabetes mellitus was associated with a sixfold increased
isk of PMI compared to nondiabetic patients and a risk that
as even higher than in known diabetics.
Incidence of PMI, the most common adverse event after
tent implantation, ranges from 2% to 20%.10,11 Various
tudies have shown that PMI can be associated with an
nferior clinical outcome.1,2,11,12 Risk factors for occurrence
f PMI are factors that are associated with an increase of the
eneral atherosclerotic burden such as presence of multi-
essel disease, lesion eccentricity and calcification, throm-
us formation, advanced age, and overt diabetes melli-
us.13,14 Increased risk of adverse events in diabetic patients
undergoing PCI persisted after the introduction of DES and
was seen in patients treated with first- and second-genera-
tion DESs.14–17
Studies have shown that even patients without a history
of diabetes mellitus but with increased HbA1c levels (i.e.,
undetected diabetics) have an increased risk of cardiovas-
cular complications,18,19 but the relation between unde-
tected diabetes mellitus and PMI has yet not been investi-
gated. We hypothesized that patients with undetected (and
thus untreated) diabetes mellitus may be prone to PMI
because their metabolic dysregulation with its long-term
hyperglycemic state leads to dyslipidemia, increased ather-
oma burden, hypercoagulability, vessel wall inflammation,
o DM
 400)
Known DM
(n  180)
p Value
Undetected vs
No DM
Undetected vs
Known DM
(1.8%) 5 (2.8%) 1.00 0.59
(1.3%) 4 (2.2%) 1.00 1.00
(3.3%) 10 (5.6%) 1.00 0.70
(4.0%) 14 (7.8%) 0.02 0.24
(3.8%) 11 (6.1%) 0.01 0.11
(0.3%) 3 (1.7%) 1.00 1.00
(8.0%) 24 (13.3%) 0.25 0.96
(10.5%) 31 (17.2%) 0.45 0.57
(4.8%) 15 (8.3%) 0.71 0.21
(7.0%) 19 (10.6%) 0.34 0.14
(0.8%) 3 (0.8%) 1.00 1.00
ite end point is a composite consisting of all-cause death, any myocardialN
(n
7
5
13
16
15
1
32
42
19
28
3
composand vulnerable plaques.3–5,20
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1566 The American Journal of Cardiology (www.ajconline.org)In the present study, undetected diabetics had a signifi-
cantly increased risk of PMI compared to nondiabetic patients.
PMI may result from macro- or microvascular complications
but we did not observe any difference in macrovascular com-
plications such as side branch occlusion or evident distal em-
bolization. This suggests that differences in the incidence of
PMI between patient groups may reflect differences in micro-
vascular dysfunction or microvascular obstruction, which may
be caused by periprocedural microembolization of athero-
thrombotic debris as suggested by Böse et al.21
A recent study by Timmer et al19 in nondiabetic patients
with ST-segment elevation MI and our present data suggest
that a considerable proportion of patients with coronary
artery disease are undetected diabetics. As the global dis-
ease burden of diabetes mellitus increases,22 the number of
undetected diabetics requiring PCI also is likely to increase.
Measurement of HbA1c levels is reproducible and feasible,7
and it may be a convenient means to assess patients before
PCI procedures for risk stratification and potential adjust-
ment of treatment. In the present study, undetected diabetics
had a higher PMI risk than known diabetics on antidiabetic
medication. Initiation or optimization of pharmacologic
treatment for glycemic control before PCI might decrease
the hyperglycemia-promoted increase in PMI risk.4 How-
ever, it is still unclear which pharmacologic treatment strat-
egy may be most beneficial in patients without a history of
diabetes but with increased HbA1c levels. Initiation of glu-
cose-lowering treatment may be favorable, whereas very
intensive glucose regulation could carry an additional
risk.23,24 Other measures to decrease PMI risk may be
retreatment with drugs that have anti-inflammatory and/or
ntithrombotic properties such as high-dose statins25 and/or
glycoprotein IIb/IIIa antagonists26,27 or treatment with more
ggressive antiplatelet regimens because diabetes is also
ssociated with high platelet reactivity.28
Identification of undetected diabetics may also be rele-
vant in the context of clinical studies. Most contemporary
randomized DES trials have addressed composite end
points, of which PMI is an important component.6,7,29 It
may be prudent to routinely assess the diabetic state before
patient enrollment in randomized studies to avoid clustering
of these patients in a particular study arm.
The findings of this study should be considered as
hypothesis-generating because of the relatively limited
number of undetected diabetics. Although we found sta-
tistically significant differences in PMI rates, the power
of comparison was 80% (post hoc power analysis re-
vealed that a PMI rate of 15% in the 44 undetected
diabetics would have been required to reach 80% power
at a significance level of 0.05).
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